[go: up one dir, main page]

EP3113791B1 - Nouvelles préparations d'insuline à action rapide - Google Patents

Nouvelles préparations d'insuline à action rapide Download PDF

Info

Publication number
EP3113791B1
EP3113791B1 EP15759175.1A EP15759175A EP3113791B1 EP 3113791 B1 EP3113791 B1 EP 3113791B1 EP 15759175 A EP15759175 A EP 15759175A EP 3113791 B1 EP3113791 B1 EP 3113791B1
Authority
EP
European Patent Office
Prior art keywords
insulin
preparations
preparation according
zinc
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP15759175.1A
Other languages
German (de)
English (en)
Other versions
EP3113791A4 (fr
EP3113791A1 (fr
Inventor
Klavs Holger JØRGENSEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP3113791A4 publication Critical patent/EP3113791A4/fr
Publication of EP3113791A1 publication Critical patent/EP3113791A1/fr
Application granted granted Critical
Publication of EP3113791B1 publication Critical patent/EP3113791B1/fr
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present invention relates to stable, extra rapid-acting human or monomeric insulin analog preparations for subcutaneous injection.
  • Insulin treatment of diabetic patients comprises the use of rapid-acting, intermediate-acting, long-acting and biphasic insulin preparations.
  • the rapid-acting insulin preparations have undergone a development towards preparations with still earlier onset of action; from acid solutions to neutral solutions of animal insulin, further to neutral solutions of human insulin (e.g. Actrapid® HM, Humulin® Regular and Insuman® Rapid), and finally to neutral solutions of monomeric insulin analogs. Examples of the latter are NovoRapid® based on B28Asp human insulin ("insulin aspart”), Humalog® based on B28LysB29Pro human insulin and Apidra® based on B3LysB29Glu human insulin.
  • the term "monomeric" alludes to the prevailing formation of monomers from aggregates in solutions of the analog and thereby faster absorption after subcutaneous injection, compared to human insulin, due to the construction of the analog molecule.
  • Rapid-acting insulin preparations are widely used in connection with a multiple subcutaneous injection (basal/bolus) regimen in which an intermediate-acting insulin is injected twice a day or a long-acting insulin once a day, in order to provide a basal level of plasma insulin, while a rapid-acting insulin is injected at a time most suitable for, as far as possible, normalizing the blood sugar after a meal.
  • human insulin has to be injected about 1 ⁇ 2 hour before the meal in diabetic patients, because of the retarded absorption of the insulin. Due to the faster absorption of monomeric insulin, injection can be made closer to the meal, which is more convenient for the patient.
  • monomeric insulin in plasma follows to a higher degree the pattern of plasma insulin appearance in healthy persons after a meal, thus providing an overall improved blood glucose control, including a lower rate of hypoglycaemic events.
  • the above-mentioned commercially available monomeric insulin preparations are therefore preferred for use as the rapid-acting components in a basal/bolus regimen today.
  • Nicotinamide has been shown to accelerate the absorption of subcutaneously injected human or monomeric insulin, vide USP 5,382,574 , WO/1996/010417 and WO/2010/149772 .
  • the preparations of the invention are solutions and characterized in that they (1) contain human insulin or a monomeric human insulin analog, (2) have a lower concentration of insulin-bound zinc than about 1.8 ions per hexamer of insulin, (3) contain nicotinamide, and (4) has a lower conductivity than about 0.2 mSi/cm.
  • the preferred content of insulin is in the range from about 0.2 mM to about 6 mM, preferably from about 0.4 mM to about 3 mM, more preferred from about 0.5 to about 0.7 mM.
  • the preferred content of zinc is less than about 1.2, preferably less than about 0.4, more preferred less than about 0.1, most preferred less than about 0.02 insulin-bound zinc ions per hexamer of human insulin or analog.
  • a low content of insulin-bound zinc, or virtual absence of zinc, is mandatory for obtaining the extra high rate of absorption after injection of the preparations according to the invention. This can be the case, if a zinc-binding, non-insulin substance such as EDTA is present.
  • the preferred content of nicotinamide is in the range from about 10 to about 500 mM, preferably from about 25 to about 400 mM, more preferred from about 100 to about 350 mM, most preferred from about 150 to about 300 mM.
  • the conductivity is less than about 0.2 mSi/cm at 22 °C.
  • a non-ionic detergent such as polysorbate 20 (Tween 20) may be added to the preparations in order to improve physical stability.
  • the preferred concentration of non-ionic detergent ranges from about 5 to about 50 ppm.
  • Non-ionic detergents are well known as stabilizers of protein solutions.
  • the range of pH is from about 6.0 to about 8.0, preferably from about 6.3 to about 7.5.
  • the preferred preservative is m-cresol, since solutions of insulins with low contents of zinc have a tendency to precipitate with addition of phenol, but not with addition of m-cresol.
  • concentrations of the components required according to the invention, makes the preparations hypotonic, non-ionic excipients must be added in order to make the preparations isotonic.
  • the mobile phase consisted of A: Water, 0.1% v/v trifluoroacetic acid and B: Acetonitrile, 0.07% v/v trifluoroacetic acid. Elution was performed at a rate of 1 ml/min and at 40°C after the following schedule:
  • the retained solutions were mixed with water to the original volumes. The volumes were again reduced 7 times. The retained volumes were pooled and the insulin concentration measured by HPLC. The pool was used for making a preparation with 0.6 mM zink free human insulin, 0.27 M nicotinamide and 0.028 M m-cresol. The conductivity at 22° C was 0.085 mSi/cm. HPLC of the filtrates showed that less than 1% of the total amount of insulin had passed the filters.
  • preparations 1-6 described in Examples I-III are made from the commercial preparations Actrapid and NovoRapid, the preparation described in Example IV is made from dry insulin powder being a technically relevant starting material for large scale production of preparations according to the present invention.
  • Example V also describes ultrafiltration as an alternative method for desalting compared to the precipitation technique described in Examples I-III.
  • USP 5,382,574 deals with preparations comprising insulin or an insulin derivative and nicotinamide or nicotinic acid or a salt thereof.
  • Examples 9 and 10 in this Application describe preparations containing nicotinamide and zinc free BlOAsp human insulin, a monomeric analog. In both examples the absorption of analog after subcutaneous injection of the preparation in pigs was found to be considerably faster than that of a reference preparation containing zinc free analog without nicotinamide, thus demonstrating the absorption promoting effect of nicotinamide, which is the essence of USP 5,382,574 .
  • Examples 9 and 10 did not reveal the impact of zinc concentration on the absorption rate of the analog in preparations with nicotinamide. Neither the salt content of the applied zinc-free analog, nor the conductivities of the preparation, nor the stability of the preparations were disclosed.
  • Example 7 in the same application describes a preparation containing nicotinamide and human insulin with 3 Zn ++ per hexamer.
  • the time until half of the insulin had disappeared after subcutaneous injection of the preparation in pigs was found to be 22 % lower than that of a reference preparation with 3 Zn ++ per hexamer (composed as Actrapid) and without nicotinamide.
  • Example 4 in the same application describes a preparation containing nicotinamide, zinc free human insulin.
  • the time until half of the insulin had disappeared after subcutaneous injection of the preparation in pigs was found to be about 46 % lower than that of a reference preparation with 3 Zn ++ per hexamer (composed as Actrapid) without nicotinamide.
  • a reference preparation with 3 Zn ++ per hexamer Composed as Actrapid
  • the earlier mentioned WO/1996/010417 deals with preparations containing insulin aspart and nicotinamide.
  • the only example in the Application describes a test preparation containing 0.6 mmol analog, 3 zinc ions/hexamer, 0.26 mM nicotinamide and 3 g/l phenol (pH 7.4) and a reference preparation with nicotinamide substituted by 16 g/l glycerol.
  • the test preparation revealed a significantly earlier decrease in plasma glucose and a significantly faster absorption than the reference preparation after subcutaneous injection.
  • the time until half of the insulin had disappeared after subcutaneous injection of the preparations in pigs was found to be about 24 % lower than that of a reference preparation.
  • the present invention reveals that nicotinamide-containing insulin preparations with extra rapid action after subcutaneous injection can be made sufficiently stable when combined with low concentrations of zinc and low conductivities.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (12)

  1. Préparation pour injection à des humains comprenant : (1) une solution d'insuline humaine ou un analogue d'insuline monomère, (2) du zinc lié à l'insuline en une concentration inférieure à environ 1,8 ion par hexamère d'insuline, (3) du nicotinamide, et dans laquelle la conductivité est inférieure à environ 0,2 mSi/cm à 22 °C.
  2. Préparation selon la revendication 1, dans laquelle l'insuline est l'insuline humaine.
  3. Préparation selon la revendication 1, dans laquelle l'analogue d'insuline est la B28Asp-insuline humaine.
  4. Préparation selon la revendication 1, dans laquelle l'analogue d'insuline est la B28LysB29Pro-insuline humaine.
  5. Préparation selon la revendication 1, dans laquelle l'analogue d'insuline est la B3LysB29Glu-insuline humaine.
  6. Préparation selon l'une quelconque des revendications précédentes, caractérisée en ce que la concentration en insuline humaine ou en analogue d'insuline se trouve dans la plage d'environ 0,2 mM à environ 6 mM, de préférence d'environ 0,4 mM à environ 3 mM, de manière davantage préférée d'environ 0,5 mM à environ 0,7 mM.
  7. Préparation selon l'une quelconque des revendications précédentes, caractérisée en ce que la préparation contient moins d'environ 1,2, de préférence moins d'environ 0,4, de manière davantage préférée moins d'environ 0,1, de manière préférée entre toutes moins d'environ 0,02 ion de zinc lié à l'insuline par hexamère d'insuline humaine ou d'insuline monomère.
  8. Préparation selon l'une quelconque des revendications précédentes, caractérisée en ce que la concentration en nicotinamide se trouve dans la plage d'environ 10 à environ 500 mM, de préférence d'environ 25 à environ 400 mM, de manière davantage préférée d'environ 100 à environ 350 mmol, de manière préférée entre toutes d'environ 150 à environ 300 mM.
  9. Préparation selon l'une quelconque des revendications précédentes, caractérisée en ce qu'elle contient un détergent non ionique, de préférence dans la plage de concentration d'environ 5 à environ 50 ppm.
  10. Préparation selon l'une quelconque des revendications précédentes, caractérisée en ce que le pH se trouve dans la plage d'environ 6,0 à environ 8,0, de préférence d'environ 6,3 à environ 7,5.
  11. Préparation selon l'une quelconque des revendications précédentes, caractérisée en ce qu'elle contient un conservateur, de préférence du m-crésol dans la plage de concentration d'environ 10 à 40 mM.
  12. Préparation injectable selon l'une quelconque des revendications précédentes, ladite préparation étant destinée à une utilisation en tant que médicament pour le traitement ou la prévention du diabète sucré.
EP15759175.1A 2014-03-07 2015-03-06 Nouvelles préparations d'insuline à action rapide Not-in-force EP3113791B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201400125 2014-03-07
DKPA201400171 2014-03-26
PCT/DK2015/000010 WO2015131902A1 (fr) 2014-03-07 2015-03-06 Nouvelles préparations d'insuline à action rapide

Publications (3)

Publication Number Publication Date
EP3113791A4 EP3113791A4 (fr) 2017-01-11
EP3113791A1 EP3113791A1 (fr) 2017-01-11
EP3113791B1 true EP3113791B1 (fr) 2018-12-26

Family

ID=54054597

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15759175.1A Not-in-force EP3113791B1 (fr) 2014-03-07 2015-03-06 Nouvelles préparations d'insuline à action rapide

Country Status (3)

Country Link
US (1) US20170028031A1 (fr)
EP (1) EP3113791B1 (fr)
WO (1) WO2015131902A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5749155B2 (ja) 2008-03-18 2015-07-15 ノボ・ノルデイスク・エー／エス プロテアーゼ安定化アシル化インスリンアナログ
WO2018109162A1 (fr) 2016-12-16 2018-06-21 Novo Nordisk A/S Compositions pharmaceutiques contenant de l'insuline

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0506792B1 (fr) * 1989-12-21 1995-05-17 Novo Nordisk A/S Preparations d'insuline contenant de l'acide nicotinique ou de la nicotinamide
US6693094B2 (en) * 2001-03-22 2004-02-17 Chrono Rx Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
MX2011012764A (es) * 2009-06-26 2012-01-20 Novo Nordisk As Preparacion que comprende insulina, nicotinamida y un aminoacido.
MX2013006174A (es) * 2010-12-14 2013-07-15 Novo Nordisk As Preparacion que comprende insulina, nicotinamida y un aminoacido.
WO2013186138A1 (fr) * 2012-06-14 2013-12-19 Novo Nordisk A/S Préparation comprenant de l'insuline, du nicotinamide et de l'arginine
HK1217443A1 (zh) * 2013-01-29 2017-01-13 奥莎迪药品管理有限公司 用於糖尿病的口服治疗的药物组合物
AR099569A1 (es) * 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
EP3113791A4 (fr) 2017-01-11
EP3113791A1 (fr) 2017-01-11
US20170028031A1 (en) 2017-02-02
WO2015131902A1 (fr) 2015-09-11

Similar Documents

Publication Publication Date Title
JP7531564B2 (ja) インスリン分泌性ペプチドの安定な水性非経口医薬組成物
KR100987311B1 (ko) 아연을 전혀 포함하지 않거나 소량의 아연만을 포함한 개선된 안정성을 가지는 인슐린 제형
EP0921812B2 (fr) Preparations d'insuline contenant du halogenide
US20150119323A1 (en) Stable Formulation of Insulin Glulisine
Brange et al. Neutral insulin solutions physically stabilized by addition of Zn2+
KR102482664B1 (ko) 신규한 제제
EP3452079B1 (fr) Formulations d'insuline comprenant du polysorbate 80
EP3554534B1 (fr) Compositions pharmaceutiques contenant de l'insuline
EA028572B1 (ru) Стабильная композиция для парентеральной инъекции и способы ее получения и использования
CN105126082B (zh) 一种多肽药物制剂及其制备方法
KR20150021011A (ko) 초고도 농축된, 속효성 인슐린 유사체 제형
WO2014011629A1 (fr) Formulations aqueuses stables d'étanercept
IE910579A1 (en) Novel protein compositions
EP3113791B1 (fr) Nouvelles préparations d'insuline à action rapide
CN103830189A (zh) 一种重组甘精胰岛素制剂及其制备方法
CN105597087B (zh) 一种甘精胰岛素注射液及其制备方法
EP4257120A1 (fr) Composition solide de fosphénytoïne sodique, procédé de lyophilisation et utilisation de la composition solide de fosphénytoïne sodique
HK40043780A (en) Insulin containing pharmaceutical compositions
HK40043780B (en) Insulin containing pharmaceutical compositions
JPWO2019147718A5 (fr)
CN120919043A (zh) 一种药物组合物及其在降糖减重药物中的应用
CN103655468A (zh) 一种促胰岛素分泌肽融合蛋白Exendin-4-HSA溶液稳定制剂
HK40008567A (en) Insulin containing pharmaceutical compositions
HK40008567B (en) Insulin containing pharmaceutical compositions

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20160926

A4 Supplementary search report drawn up and despatched

Effective date: 20161209

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20170814

R17C First examination report despatched (corrected)

Effective date: 20170814

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20180619

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAR Information related to intention to grant a patent recorded

Free format text: ORIGINAL CODE: EPIDOSNIGR71

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20181115

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1080489

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190115

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015022361

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181226

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190326

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181226

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190326

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181226

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181226

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20181226

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181226

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190327

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181226

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181226

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1080489

Country of ref document: AT

Kind code of ref document: T

Effective date: 20181226

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181226

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190426

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181226

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181226

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181226

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181226

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190426

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181226

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181226

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181226

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181226

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20190627

Year of fee payment: 5

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602015022361

Country of ref document: DE

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20190627

Year of fee payment: 5

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602015022361

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181226

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181226

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181226

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20190515

Year of fee payment: 5

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190306

26N No opposition filed

Effective date: 20190927

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20190331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191001

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190306

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190331

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181226

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181226

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190306

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200331

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200331

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200331

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20200306

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200306

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181226

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20150306

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181226